Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Relationship Between Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Cancer

NCT01017731 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01017731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01017731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Relationship Between Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2009
Completion date
May 31, 2014
Enrollment
68 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, solid tumor